No profile data available.
Skye Bioscience, Inc. (SKYE) is a healthcare company in the obesity treatment pharmaceuticals industry, based in San Diego, United States, with about 2 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$55.92 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $7.48 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases.
Skye Bioscience reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$7.48 million as of October 9, 2026.
Listed companies of a similar size in the same industry (obesity treatment pharmaceuticals) include Structure Therapeutics Inc. (GPCR), BioAge Labs, Inc. (BIOA), Aardvark Therapeutics, Inc. (AARD), Artelo Biosciences, Inc. (ARTL).